Meng-Jie Huang1, Ri-Bao Wei2, Zi-Cheng Wang1, Yue Xing1, Yu-Wei Gao1, Min-Xia Li1, Guang-Yan Cai1, Xiang-Mei Chen1. 1. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China. 2. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China. Electronic address: wrbbj2006@126.com.
Abstract
INTRODUCTION: Thromboelastography (TEG) was performed to assess potential hypercoagulability in Nephrotic syndrome (NS) patients with membranous nephropathy (MN) and to explore correlated factors contributing to hypercoagulable status MATERIALS AND METHODS: 101 MN patients, 61 minimal change disease (MCD) patients and 20 healthy controls met the inclusion criteria. The MN and MCD patients were stratified into two layers according to serum albumin (SALB) levels (<20g/l or 20-30g/l). Primary outcome measures included reaction time (R), α-angle, maximum amplitude (MA) and coagulation index (CI). TEG parameters of four patient subgroups were analyzed in factorial designed ANOVA with factors disease and SALB. RESULTS: By linear regression analysis, TEG parameters in MN patients correlated with SALB (P<0.01) and the ANOVA for factorial designed data confirmed that the main effects of factors SALB and disease were both statistically significant. Besides, comparison between control group and patient subgroups showed that R value in normal controls was significantly higher than that in MN subgroups, but was not statistically different from that in MCD subgroups. NS patients (MCD, MN) had significantly higherα-angle, MA and CI values than healthy controls (p<0.05). CONCLUSIONS: MN patients tend to be more hypercoagulable than normal and MCD patients. Hypercoagulability in MN patients involves the whole thrombotic processes acceleration (activated intrinsic pathway, fibrinogen, platelet function and fibrin-platelet interaction), whereas hypercoagulable state in MCD patients may be that the coagulation factors are not fully activated. Greater efforts should be made to prevent hypercoagulability especially for MN patients with severe hypoalbuminemia.
INTRODUCTION: Thromboelastography (TEG) was performed to assess potential hypercoagulability in Nephrotic syndrome (NS) patients with membranous nephropathy (MN) and to explore correlated factors contributing to hypercoagulable status MATERIALS AND METHODS: 101 MN patients, 61 minimal change disease (MCD) patients and 20 healthy controls met the inclusion criteria. The MN and MCDpatients were stratified into two layers according to serum albumin (SALB) levels (<20g/l or 20-30g/l). Primary outcome measures included reaction time (R), α-angle, maximum amplitude (MA) and coagulation index (CI). TEG parameters of four patient subgroups were analyzed in factorial designed ANOVA with factors disease and SALB. RESULTS: By linear regression analysis, TEG parameters in MN patients correlated with SALB (P<0.01) and the ANOVA for factorial designed data confirmed that the main effects of factors SALB and disease were both statistically significant. Besides, comparison between control group and patient subgroups showed that R value in normal controls was significantly higher than that in MN subgroups, but was not statistically different from that in MCD subgroups. NSpatients (MCD, MN) had significantly higherα-angle, MA and CI values than healthy controls (p<0.05). CONCLUSIONS: MN patients tend to be more hypercoagulable than normal and MCDpatients. Hypercoagulability in MN patients involves the whole thrombotic processes acceleration (activated intrinsic pathway, fibrinogen, platelet function and fibrin-platelet interaction), whereas hypercoagulable state in MCDpatients may be that the coagulation factors are not fully activated. Greater efforts should be made to prevent hypercoagulability especially for MN patients with severe hypoalbuminemia.
Authors: Daniel A Muruve; Hanna Debiec; Simon T Dillon; Xuesong Gu; Emmanuelle Plaisier; Handan Can; Hasan H Otu; Towia A Libermann; Pierre Ronco Journal: Kidney Int Rep Date: 2022-04-14
Authors: Amanda P Waller; Jonathan P Troost; Samir V Parikh; Katelyn J Wolfgang; Brad H Rovin; Marvin T Nieman; William E Smoyer; Matthias Kretzler; Bryce A Kerlin Journal: Thromb Res Date: 2021-02-16 Impact factor: 3.944
Authors: Angelica Botto; Barbara Bruno; Cristiana Maurella; Fulvio Riondato; Alberto Tarducci; Giulio Mengozzi; Antonio Borrelli Journal: BMC Vet Res Date: 2018-01-31 Impact factor: 2.741